VEGF polymorphisms and severity of atherosclerosis

Area of Science:

• Genetics
• Cardiovascular Disease
• Molecular Biology

Background:

• Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis, playing a role in atherosclerotic plaque development.
• The precise role of VEGF in atherosclerosis (pro-atherosclerotic or anti-atherosclerotic) remains debated.
• Investigating functional single nucleotide polymorphisms (SNPs) in the VEGF gene can clarify its involvement.

Purpose of the Study:

• To determine the association between specific VEGF gene polymorphisms and coronary atherosclerosis.
• To clarify whether VEGF acts as a protective or detrimental factor in the development of atherosclerosis.

Main Methods:

• Genotyping of three reportedly functional VEGF single nucleotide polymorphisms (SNPs): -2578, -1154, and -634.
• Analysis conducted in 984 well-documented coronary atherosclerosis patients from the Southampton Atherosclerosis Study.
• Utilized the 5' nuclease assay (TaqMan) for allelic discrimination.

Main Results:

• The VEGF -2578 CC genotype was significantly associated with a protective effect against atherosclerosis, showing a different distribution in patients without myocardial infarction and correlating with fewer diseased arteries.
• The AA genotype at VEGF -2578 was identified as a risk factor for atherosclerosis.
• VEGF haplotypes also showed associations with the number of diseased arteries and stenotic segments, consistent with a protective role for higher VEGF expression (associated with CC genotype).

Conclusions:

• Preliminary evidence suggests VEGF gene polymorphism is linked to atherosclerosis development, potentially through regulation of VEGF expression.
• Findings support a protective role for VEGF in atherosclerosis.
• Replication in independent cohorts and investigation of additional VEGF polymorphisms are recommended.